NIKKEI 225
38,073.98 -128.39 (-0.34%) HANG SENG
18,537.81 +223.95 (+1.22%) CRUDE OIL
79.57 +0.58 (+0.73%) GOLD FUTURES
2,353.10 +30.80 (+1.33%) DOW
39,387.76 +331.37 (+0.85%) Bitcoin GBP
50,140.02 +1,013.00 (+2.06%)
Ironwood Pharmaceuticals, Inc. (IRWD)
After hours:
| Previous close | 8.12 |
| Open | 6.84 |
| Bid | 6.69 x 200 |
| Ask | 6.78 x 200 |
| Day's range | 6.21 - 7.22 |
| 52-week range | 6.21 - 15.70 |
| Volume | |
| Avg. volume | 4,538,570 |
| Market cap | 1.071B |
| Beta (5Y monthly) | 0.57 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Ironwood Pharmaceuticals Reports First Quarter 2024 Results
BOSTON, May 09, 2024--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today reported its first quarter 2024 results and recent business performance.
- Business Wire
Ironwood Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference
BOSTON, May 06, 2024--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at The Citizens JMP Life Sciences Conference on Monday, May 13, 2024 at 10:00 a.m. ET at the New York Hilton Midtown.
- Business Wire
Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week® 2024
BOSTON, May 01, 2024--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, announced today that the company will present new data from studies evaluating apraglutide in adults with short bowel syndrome with intestinal failure (SBS-IF), a condition in which patients are dependent on parenteral support (PS), during the 2024 Digestive Disease Week® (DDW) meeting. DDW is held from May 18-21, 2024, in Washington, D.C.
